Supplementary Materials

The PDF file includes:

  • Material and Methods
  • Fig. S1. Changes in T cell subsets in patients with RRMS on teriflunomide treatment.
  • Fig. S2. Influence of teriflunomide on proliferation and cytokine production.
  • Fig. S3. Impact of antigen affinities and DHODH interference on proliferation.
  • Fig. S4. Metabolic assessment of T cells under teriflunomide treatment.
  • Fig. S5. Influence of DHODH inhibition on T cell metabolism, on gene expression of OT-I and OT-III T cells, on TH1 differentiation and proliferation, and on Treg subpopulations in EAE.
  • Fig. S6. Metabolism of T cells from patients with RRMS and HCs.
  • Fig. S7. Comparison of freshly isolated versus frozen PBMCs from HCs regarding immune cell subset composition and metabolism.
  • Fig. S8. Additional information supporting methodology.
  • Table S1. Demographics and baseline disease characteristics TERIDYNAMIC trial.
  • Table S2. Differentially regulated genes depicted in Fig. 5I.
  • Table S3. Demographics and baseline disease characteristics of HCs and treatment-naïve patients analyzed for TCR repertoire changes.
  • Table S4. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment analyzed for TCR repertoire changes.
  • Table S5. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment analyzed for immune cell phenotyping.
  • Table S6. Demographics and baseline disease characteristics of patients before and during teriflunomide treatment for at least 6 months analyzed for suppressive capacity of Tregs.
  • Table S7. Demographics and baseline disease characteristics of patients before and during teriflunomide treatment for at least 6 months analyzed for cytokine expression of Tregs.
  • Table S8. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment for at least 6 months analyzed for myelin-specific T cell frequencies.
  • Table S9. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment for at least 6 months analyzed for metabolic activity.
  • Table S10. Demographics and baseline disease characteristics of treatment-naïve patients before and during treatment with DMF, IFN-β, or GLAT analyzed for TCR repertoire changes.
  • Table S11. Demographics and baseline disease characteristics of HCs and treatment-naïve patients analyzed for metabolic activity.
  • Table S12. Demographics and baseline disease characteristics of HCs and patients analyzed for metabolic activity after 72 hours of in vitro stimulation.
  • Table S13. Demographics of HCs analyzed for immune cell phenotyping of freshly isolated versus frozen PBMCs.
  • Table S14. Demographics of HCs analyzed for metabolic differences of T cells isolated from fresh blood or frozen PBMCs.
  • References (3638)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: